Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Vraylar topic
No spam. Unsubscribe anytime.
PDAB votes 6-1 to identify Vraylar for affordability review
Summary
The Oregon Prescription Drug Affordability Board voted 6-1 on Jan. 21, 2026, to identify Vraylar (cariprazine HCl) as a drug that may create affordability challenges, with a single dissenting vote from board member Chris Laman.
On Jan. 21, 2026, the Oregon Prescription Drug Affordability Board approved a motion to identify Vraylar (cariprazine HCl) as a product that may create affordability challenges. The motion was moved by Dan Kennedy and seconded by Michele Koder and passed 6-1; board member Chris Laman cast the lone No vote.
The vote is recorded in the meeting minutes and the product appears as "YES" in Table 1 of the PDAB minutes. The board directed staff to include the identification and any associated recommendations in its 2025 drug review report to the Legislature.
